@article {8010,
	title = {Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience},
	journal = {Gynecologic Oncology},
	volume = {97},
	year = {2005},
	note = {Cited By :49Export Date: 21 February 2017},
	month = {2005},
	pages = {436 - 441},
	abstract = {Objective. Mucinous epithelial ovarian cancer (mEOC) representing about 10\% of all EOC are known to be possibly resistant to platinum-based chemotherapy and bear a poorer prognosis with respect to other subtypes of EOC. This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC). Methods. A retrospective analysis was performed in 47 patients with advanced stage of mEOC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 6/7/1983 and 25/2/2003. The outcome was compared to that of 94 patients with sEOC treated with the same protocols during the same study period (ratio mucinous: serous 1:2). Results. One hundred forty-one patients (47 stages III and IV mEOC, 94 stages III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for mEOC was 38.5\% (complete remission 18\%) (95\% CI 23.4-55.4\%) and 70\% (complete remission 47\%) (95\% CI 58.5-80.3\%) for sEOC (P = 0.001). After a median follow-up of 77.8 months, median survival and time to tumor progression (TTP) were not significantly different between the two groups (33.2 months [95\% CI 23.3-43.1 months] vs. 38.0 months [95\% CI 26.8-49.2 months], P = 0.46, 11.8 months [95\% CI 7.2-16.4 months] vs. 20.0 months [95\% CI 15.7-24.2 months], P = 0.18, respectively). Conclusion. Patients with mEOC have significantly lower response to first-line platinum-based chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in inferior TTP or survival. Our data indicate that a new strategy for chemotherapy in mEOC should be adopted, one that focuses on new agents without cross-resistance to platinum agents. {\textcopyright} 2005 Elsevier Inc. All rights reserved.},
	keywords = {Mucinous epithelial ovarian cancer, Platinum-based chemotherapy, Response, Survival},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-20944439079\&doi=10.1016\%2fj.ygyno.2004.12.056\&partnerID=40\&md5=b8b8d79d0411f30f7e80854de0c63994},
	author = {Pectasides, D. and Fountzilas, G. and Aravantinos, G. and Kalofonos, H.P. and Efstathiou, E. and Salamalekis, E. and Farmakis, D. and Skarlos, D. and Briasoulis, E. and Economopoulos, T. and Dimopoulos, M.A.}
}
